LH Stock Forecast 2025-2026
Distance to LH Price Targets
LH Price Momentum
10 Quality Stocks Worth Considering Now
Researching LabCorp (LH) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on LH and similar high-potential opportunities.
Latest LH Stock Price Targets & Analyst Predictions
Based on our analysis of 33 Wall Street analysts, LH has a bullish consensus with a median price target of $275.00 (ranging from $232.12 to $300.00). The overall analyst rating is Strong Buy (8.7/10). Currently trading at $231.67, the median forecast implies a 18.7% upside. This outlook is supported by 14 Buy, 5 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Ralph Giacobbe at Citigroup, projecting a 29.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LH Analyst Ratings
LH Price Target Range
Latest LH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 4, 2025 | Citigroup | Ralph Giacobbe | Buy | Upgrade | $300.00 |
| Feb 10, 2025 | Piper Sandler | David Westenberg | Neutral | Maintains | $260.00 |
| Feb 7, 2025 | Barclays | Jack Meehan | Equal-Weight | Maintains | $260.00 |
| Feb 6, 2025 | Jefferies | Tycho Peterson | Buy | Maintains | $290.00 |
| Feb 3, 2025 | Barclays | Jack Meehan | Equal-Weight | Maintains | $271.00 |
| Jan 28, 2025 | UBS | Kevin Caliendo | Buy | Maintains | $286.00 |
| Jan 7, 2025 | Evercore ISI Group | Elizabeth Anderson | Outperform | Upgrade | $265.00 |
| Dec 17, 2024 | Morgan Stanley | Ricky Goldwasser | Overweight | Maintains | $270.00 |
| Dec 13, 2024 | B of A Securities | Derik De Bruin | Buy | Maintains | $271.00 |
| Dec 10, 2024 | Jefferies | Brian Tanquilut | Buy | Initiates | $275.00 |
| Oct 30, 2024 | HSBC | Morten Herholdt | Buy | Upgrade | $0.00 |
| Oct 28, 2024 | Piper Sandler | David Westenberg | Neutral | Maintains | $240.00 |
| Oct 25, 2024 | Baird | Eric Coldwell | Outperform | Maintains | $289.00 |
| Oct 25, 2024 | Barclays | Jack Meehan | Equal-Weight | Maintains | $249.00 |
| Oct 16, 2024 | Barclays | Jack Meehan | Equal-Weight | Maintains | $234.00 |
| Oct 1, 2024 | Piper Sandler | David Westenberg | Neutral | Initiates | $235.00 |
| Sep 24, 2024 | Evercore ISI Group | Elizabeth Anderson | In-Line | Maintains | $240.00 |
| Sep 23, 2024 | Jefferies | Brian Tanquilut | Buy | Maintains | $265.00 |
| Sep 20, 2024 | Baird | Eric Coldwell | Outperform | Maintains | $282.00 |
| Aug 5, 2024 | B of A Securities | Derik De Bruin | Buy | Maintains | $260.00 |
Labcorp Holdings Inc. (LH) Competitors
The following stocks are similar to LabCorp based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Labcorp Holdings Inc. (LH) Financial Data
Labcorp Holdings Inc. has a market capitalization of $19.53B with a P/E ratio of 26.4x. The company generates $13.01B in trailing twelve-month revenue with a 5.7% profit margin.
Revenue growth is +9.8% quarter-over-quarter, while maintaining an operating margin of +6.9% and return on equity of +9.4%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Labcorp Holdings Inc. (LH) Business Model
About Labcorp Holdings Inc.
Provides comprehensive laboratory services for healthcare.
Labcorp operates by offering a wide range of diagnostic testing services, generating revenue through clinical laboratory services, drug development, and commercialization. Its subsidiary, Covance, enhances earnings by supporting pharmaceutical and biotechnological research, making it a key player in the healthcare ecosystem.
Headquartered in Burlington, North Carolina, Labcorp has been a significant contributor to healthcare since 1978, focusing on areas such as oncology, cardiology, and infectious diseases. The company's services are essential for healthcare providers, impacting patient care and advancing medical research.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
60,900
CEO
Mr. Adam H. Schechter
Country
United States
IPO Year
1990
Website
www.labcorp.comLabcorp Holdings Inc. (LH) Latest News & Analysis
Zacks Premium offers Style Scores to help value, growth, and momentum investors identify strong stocks more easily.
Zacks Style Scores can enhance stock selection across investment strategies, potentially leading to better returns and informed decision-making for investors.
LH has signed an agreement to acquire BioReference Health's oncology and related clinical testing services businesses.
The acquisition expands LH's service offerings in oncology, potentially increasing revenue and market share, signaling growth opportunities that can positively influence stock performance.
Labcorp (NYSE: LH) has announced an agreement to acquire select assets of BioReference Health from OPKO Health (Nasdaq: OPK), enhancing its oncology services and laboratory offerings.
Labcorp's acquisition enhances its oncology dominance and broadens clinical services, potentially increasing revenue and market share, which may positively impact stock performance.
LH is attracting investor attention due to its emphasis on high-growth sectors and its strategy of pursuing strategic acquisitions.
LH's focus on high-growth areas and strategic acquisitions signals potential for increased revenue and market share, making it an attractive investment opportunity.
Labcorp launched Labcorp® Plasma CompleteTM, a ctDNA-based genomic profiling solution for advanced solid tumors, enhancing oncologists' diagnostic capabilities.
Labcorp's new ctDNA profiling solution enhances cancer diagnostics, potentially increasing demand for their services and revenues, impacting stock performance and market positioning.
Here's Why Labcorp (LH) is a Strong Value Stock
1 month agoZacks Style Scores help investors identify top-rated stocks tailored to their investing style, providing a streamlined approach for stock selection.
The Zacks Style Scores help identify high-potential stocks tailored to specific investing strategies, enhancing stock-picking efficiency and potentially improving portfolio performance.
Frequently Asked Questions About LH Stock
What is Labcorp Holdings Inc.'s (LH) stock forecast for 2025?
Based on our analysis of 33 Wall Street analysts, Labcorp Holdings Inc. (LH) has a median price target of $275.00. The highest price target is $300.00 and the lowest is $232.12.
Is LH stock a good investment in 2025?
According to current analyst ratings, LH has 14 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $231.67. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LH stock?
Wall Street analysts predict LH stock could reach $275.00 in the next 12 months. This represents a 18.7% increase from the current price of $231.67. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Labcorp Holdings Inc.'s business model?
Labcorp operates by offering a wide range of diagnostic testing services, generating revenue through clinical laboratory services, drug development, and commercialization. Its subsidiary, Covance, enhances earnings by supporting pharmaceutical and biotechnological research, making it a key player in the healthcare ecosystem.
What is the highest forecasted price for LH Labcorp Holdings Inc.?
The highest price target for LH is $300.00 from Ralph Giacobbe at Citigroup, which represents a 29.5% increase from the current price of $231.67.
What is the lowest forecasted price for LH Labcorp Holdings Inc.?
The lowest price target for LH is $232.12 from at , which represents a 0.2% increase from the current price of $231.67.
What is the overall LH consensus from analysts for Labcorp Holdings Inc.?
The overall analyst consensus for LH is bullish. Out of 33 Wall Street analysts, 14 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $275.00.
How accurate are LH stock price projections?
Stock price projections, including those for Labcorp Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
